GALECTO INC (GLTO)

Company Profile

Galecto Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 13 full-time employees. The company went IPO on 2020-10-29. Galecto, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on developing novel treatments for cancer and liver diseases. The Company’s pipeline consists small molecule drug candidates that target cancer and fibrosis signaling pathways, including an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications; and a preclinical dual inhibitor of ENL-YEATS and FLT3 (BRM-1420) for multiple genetic subsets of acute myeloid leukemia (AML). The GB1211, is also being developed for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.

Company Info

GALECTO INC

75 State Street, Suite 100

Boston MASSACHUSETTS DK-2200

P: 14570705210

CEO: Hans T. Schambye

Employees: 13

Website: https://galecto.com/